Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please tell me more. What would the grounds be for appeal? What did the judge do wrong?
If a buyout is being held up because of the Generic case, a win by Amarin would seal the deal for the buyout. An Appeal which would likely get dismissed, would not stop a buyout.
Jefferies Financial Group Raises Amarin FY2021 Earnings Estimates to $0.66 EPS (Previously $0.62). theenterpriseleader.com/202... $AMRN
At least one group putting out positive headline this morning.
Once everyone reads the closing arguments though they will know generics do not have a case.
I would add February 28th Closing argument documents filed.
It is far cheaper to extend one then to have to create one from scratch in the future.
Relax, This form needs to be renewed every three years.
20 years of watching biotech trade.
Shorts are flushing out longs and going long themselves. High volume, big flush. There will be a rebound. It may be faster than the downturn.
So my take, guidance is way too conservative. They used a model based on how many new reps and what a standard rep can bring in. They did not take into account the new indication or even how Vascepa had higher uptake with the last round of reps. This guidance will be updated and increased many times throughout 2020.
The filing we did is good for the UK also, correct?
Just FYI, Format for today is a quick summary presentation and then analyst asking questions.
Amarin shares 'more interesting' after recent selloff, says JPMorgan
Read more at:
https://thefly.com/landingPageNews.php?id=3040316
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results http://dlvr.it/RQn3tX
Analyst will take JT's lead. If he said we are projecting 200m in 2021 sales in EMA, the analyst will add it to their forecast. We are going to just have to give this a little time to mature.
I am still seeing a trend in the right direction on the primary. It just was not statistically significant.
It is my understanding that the primary did have an effect, it was just not significant due to the short time frame.
Twitter seems to be buzzing. It seems they have decided we are undervalued.
From what I saw yesterday around the internet is that there was concern for the label that the ESPR drug received. Even with a cheap price it may not be well received. Stock price took a hit.
Yes, green week and green day.
As far as total market is concerned. In addition to Lovaza and Generi Lovaza scripts you would have to add in scripts for Fibrates and niacin and over the counter niacin. And then you have to add in those patients who have their triglycerides untreated right now because doctors did not understand residual risk. Then there are those taking OTC fish oil that may qualify for the label.
I disagree. The most important figures are the total Rx. That is what the revenue is based on. New Rx this time of year will be higher because of new insurance plans at the first of the year.
I have to wonder if going to law school and becoming a patent attorney might be a good move for some. You need to have the background in science but yet be okay with writing and keeping track of all that detail.
APOE4 Accelerates Development of Dementia After Stroke Is There a Role for Cerebrovascular Dysfunction?
https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.028814#.Xk60jqbA0fA.twitter
Getting insurance changes in place before your piss off the physicians and patients seems like a good plan to me. DTC will be here soon enough.
There are books regarding emotional intelligence. A person with Asbergers can learn to make the connections with others based on practice and book learning. I have seen it play out with a relative.
One more migrane suggestion. Sometimes sinus pressure and fluid in the sinuses can mimic or add to symptom of migraine. A non-drowsy 24 hour Allegra D or claritin D may help keep sinus passages dry and clear to help pressure in the front of the head. They will make you thirsty so there is need for more water. Best wishes to you and your son.
According to today's PR they did.
Amarin’s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States , Canada , Lebanon and the United Arab Emirates . Amarin , together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China , the European Union and the Middle East .
Their website is not exactly clear. It says there is a related generic. Of course their actual algorithms for prescribing would be what we really need to know.
Similar Generic Drugs : Omega-3: Oral capsule, liquid filled
I would rather have pathetic volume and be stable than to have big volume and dropping.
Please let Elizabeth know and ask her to let their managed care people know.
Give it more time, 6 months.
The written closing arguments are due to the court on February 28th. That is where the case will really be spelled out and it will be clear to all that Amarin's attorneys will prevail. Once the summarys are submitted I would think we will hear from various legal experts to let us know what they think.
It is going to be several years before you have to pay Uncle Sam.
It probably did not include the new indication.
KETV is a Hearst owned channel. When you see a TV news story like this you often see it sent out to other channels with common ownership. It is likely this same news story will pop up across the country.
Currently, Hearst owns a total of 34 overall television stations.
Very nice. That type of story will do more than many sales reps.
I have access to it. He does not provide any reasons why they sold. There is nothing there, just one trader who he talked to who looks at 13fs to do her trading. Click bait.
That's ok, they raised it from a hold to a buy. Once the trial is over and scripts start exceeding the trend line they will raise the price target back up.